Selectivity at ligand targets
Key to terms and symbols		Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference amyloid β Hs Antibody Binding 9.4 pEC50 - 2 ⤷ pEC50 9.4 (EC50 4x10-10 M) [2] Description: Binding to recombinamt human Aβ 1-42

Targets where the ligand is described in the comment field
Target	Comment
triggering receptor expressed on myeloid cells 2	TREM2 is a membrane-bound receptor that contains an immunoglobulin V-set domain. It appears to function as a lipid-sensing receptor, with ligands including cyclophilin A [9], amyloid-β protein 42 [20,22], lipoprotein particles and apolipoproteins [20], and phospholipids [13]. Via interaction with TYROBP (TYROBP; DAP12) and spleen tyrosine kinase (SYK) phosphorylation, TREM2 regulates microglial survival, plasticity, migration and expression of inflammatory cytokines. Rare coding variants are associated with neurodegeneration in Alzheimer's disease [7,18-19]. The protein is an active target for the development of therapeutics for various neurodegenerative diseases [3-5,17,19,21]. VGL101 (iluzanebart), DNL919, and AL002 are agonistic TREM2-targeting monoclonal antibodies that are (or were) in clinical development for neurodegenerative diseases [11-12,14], although these are subject to limited brain permeability. This latter approach was proposed to activate TREM2-mediated microglial removal of amyloid β (Aβ) from the brain. In the phase 2 AL002 study changes resembling amyloid-related imaging abnormalities (ARIA) similar to those observed with the approved anti-Aβ monoclonals (aducanumab and lecanemab for example) were detected [12].